Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Cabozantinib | Cometriq | 4.8 Undesirable effects | Embolism arterial | Oct,2023 |
| Tirzepatide | Mounjaro | 4.8 Undesirable effects | Ileus | Oct,2023 |
| Semaglutide | Rybelsus | 4.4 Special Warnings and Special Precautions for Use | Acute Gallbladder Disease | Apr,2024 |
| Insulin Glargine; Lixisenatide | Soliqua Solostar | "4.6. Fertility, pregnancy and lactation " | Contraindicated use in women of childbearing potential not using contraception | Jul, 2024 |
| Semaglutide | Ozempic | 4.8 Undesirable effects | Risk of illeus | Oct,2023 |
| Lamotrigine | Lamictal | 4.4 Special Warnings and Special Precautions for Use | Human leukocyte antigen B (HLA-B*1502) allele in Asian has been shown to be associated with the risk of developing Stevens-Johnson syndrome/Toxic epidermal necrolysi when treated with lamotrigine. | Sep,2023 |